Please ensure Javascript is enabled for purposes of website accessibility

Maximus announces next CFO

David Mutryn to succeed Richard Nadeau in December

//January 7, 2021//

Maximus announces next CFO

David Mutryn to succeed Richard Nadeau in December

// January 7, 2021//

Listen to this article

Reston-based government services company Maximus announced Thursday the planned retirement of Chief Financial Officer Richard J. Nadeau, effective Nov. 30, 2021. David Mutryn, senior vice president of finance, will succeed Nadeau on Dec. 1, 2021.

Nadeau, who joined the company in 2014, will continue to serve as CFO through the transition.

“It has been a privilege working alongside Rick,” Maximus President and CEO Bruce Caswell said in a statement. “His valued leadership and partnership in driving the long-term strategic direction of Maximus have been critical as we continue our journey of digital transformation, clinical evolution and market expansion.”

Mutryn joined Maximus in 2016 as global corporate controller and became senior vice president of finance in 2020. He is also a member of the company’s executive committee. Before his time with Maximus, he served as vice president of finance at CSRA. He earned his bachelor’s degree from the University of Virginia and his master’s degree in business administration from the Wharton School of the University of Pennsylvania.

“Having worked with David for over a decade, I am confident that Maximus is well-positioned for the next phase of its transformation,” Nadeau said in a statement. “David Mutryn will be an exceptional addition to the senior management team.”

Founded in 1975, Maximus provides business process management and technology services. The company employs more than 30,000 people worldwide and in 2019 reported $2.9 billion in revenues. Maximus promotes itself as the nation’s largest administrator of Medicaid enrollment.

 

Subscribe to Virginia Business.

Get our daily e-newsletter.

-
YOUR NEWS.
YOUR INBOX.
DAILY.

By subscribing you agree to our Privacy Policy.